Roche is­sues vol­un­tary re­call for Susvi­mo over man­u­fac­tur­ing is­sue

It’s been al­most a year since Roche’s block­buster oc­u­lar im­plant, the wet age-re­lat­ed mac­u­lar de­gen­er­a­tion (AMD) drug Susvi­mo, was cleared for twice-an­nu­al ad­min­is­tra­tion as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER